

Quality, Purity, Functionality

Evaluating Performance Factors of Cryopreserved Peripheral Mononuclear Blood Cells



Experiment at Ease: Quality PBMCs With Minimal RBCs

Human peripheral blood mononuclear cells (PBMCs) are a mixed population of immune cells critical to both innate and adaptive immune functions. They contain a wide variety of cell types (lymphocytes, B, NK, DC and T cells) that can be isolated for specific applications or used as a whole population to model human immune physiology. There are three critical factors to consider when choosing a PBMC product: quality, purity, and functionality. Choosing Lonza's cryopreserved PBMCs guarantees all three.

Quality

Cell Count and Viability Exceeding Industry Standards

Lonza PBMCs are isolated via apheresis and density gradient separation, and come in a variety of ampule sizes to meet your research needs. Each ampule is guaranteed to provide ≥ 10 , 25, 50 or 100 million viable cells upon thawing. Post-thaw viability is guaranteed to meet an industry standard of $\geq 70\%$ in every ampoule. To demonstrate this, we randomly sampled three donor lots (Lonza CC-2702; ≥ 50 million cells) and found post-thaw averages of 54 ± 3 million cells per amp with an average % viability of 89 ± 5 (Fig. 1), clearly showing that Lonza cells greatly exceed industry benchmarks for quality.




Figure 1. Average Total Viable Cells (Millions) and Cell Viability (%) of three randomly tested lots of Lonza PBMCs guaranteed to have ≥ 50 million cells and $\geq 70\%$ viability. PBMCs were thawed, centrifuged, purged of cryopreservation medium, then resuspended in medium and counted using Trypan blue 0.4% in a 1:2 dilution and a hemocytometer.

Purity

Diverse Immune Cells, Low RBCs

Measuring immunophenotypic marker expression across the same three lots of Lonza CC-2702 PBMCs, we see a consistent and diverse spectrum of immune cell types across donors, as expected, with low levels of red blood cell contamination (Fig. 2). Percent marker expression fell within typical ranges for PBMCs (Table 1). Comparing average CD235a expression (marker expressed by red blood cells) for the same three lots of Lonza's PBMCs to that of three random lots from three competitors, we see that Lonza

PBMCs had the lowest average expression of CD235a and therefore the highest purity, indicating significantly lower contamination by red blood cells (Fig. 3).




Figure 2. Population distribution of cells averaged across three randomly tested lots of Lonza human PBMCs. Bars represent average % positive marker expression determined by immunophenotyping. The type of cell indicated by each marker is shown in parentheses. RBC = red blood cells, DC = dendritic cells, CTL = cytotoxic T cells.

Marker	Cell Type	% Positive	Typical range
CD3+	T	45.1% ± 9.9%	45 – 70%
CD4+	Helper T	44.8% ± 8.7%	25 – 60%
CD8+	Cytotoxic T	19.4% ± 4.8%	5 – 30%
CD19+	B	14.2% ± 1.3%	5 – 15%
CD56+	NK	14.5% ± 3.5%	5 – 10%
CD14+	Mono DC	27.1% ± 4.9%	10 – 30%
CD11c+	Mono DC	42.7% ± 6.6%	Unknown

Table 1. Average ± SEM % marker expression for three randomly tested lots of Lonza PBMCs (see Fig. 2) compared with typical ranges for % marker expression found in PBMCs. Our results show that Lonza PBMCs contain a diverse cell population that falls within representative ranges, another indicator of quality.




Figure 3. Purity comparison of human PBMCs between Lonza and three competing brands. Three donor lots were tested and averaged for each competitor. Bars represent % positive expression of red blood cell immunophenotyping marker CD235a+.

Functionality

The Convenience of Frozen With The Confidence of Fresh PBMCs

Lonza cryopreserved PBMCs maintain optimal functionality post-thawing. Testing the same three Lonza PBMC lots as above, average % mature dendritic cell (DC) marker expression was significantly higher after LPS stimulation, while CFSE staining showed rapid T cell proliferation when the inflammatory cytokine IL-2 was added along with CD3 and

CD28 antigens (data not shown). Furthermore, we recently developed a protocol for co-culturing DC and CD8+ T cells derived from cryopreserved PBMCs that can be found on the Lonza Bioscience [website](#).

PBMCs are used in a large variety of applications, from vaccine and drug development to immunology and disease modeling. Whether you are isolating a specific cell type or modeling complex immune responses to drugs or diseases, [Lonza cryopreserved PBMCs](#) offer the quality, purity and functionality you need to achieve your research goals. Lonza maintains inventory from a diverse donor population, allowing you to choose lots based on donor demographic characteristics to develop a representative sample group that works for you. Contact Lonza Scientific Support for more information.

Description	Catalog No.	Size
Human Peripheral Blood Mononuclear Cells (hPBMC), Cryopreserved	CC-2702	≥50 million cells
	CC-2703	≥100 million cells
	CC-2704	≥10 million cells
	CC-2705	≥25 million cells

Use Lonza's X-VIVO® 15 Serum-free Hematopoietic Cell Medium, (Lonza Cat no.: 02-053Q) for culturing PBMCs and other immune cell types. Options are available with and without gentamicin and phenol red, with native or recombinant transferrin, and for RUO vs FFM (TheraPeak®). Visit the Lonza website for more information.

Contact Us

North America

Customer Service: + 1 800 638 8174 (toll free)
order.us@lonza.com
 Scientific Support: + 1 800 521 0390 (toll free)
scientific.support@lonza.com

Europe

Customer Service: + 32 87 321 611
order.europe@lonza.com
 Scientific Support: + 32 87 321 611
scientific.support.eu@lonza.com

International

Contact your local Lonza Distributor
 Customer Service: + 1 301 898 7025
 Fax: + 1 301 845 8291
scientific.support@lonza.com

Lonza Walkersville, Inc. – Walkersville, MD 21793

For research use only. Not for use in diagnostic procedures. All trademarks belong to Lonza, and are registered in USA, EU or CH or belong to third party owners and are used only for informational purposes. All third-party copyrights have been reproduced with permission or belong to Lonza. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights. The user bears the sole responsibility for determining the existence of any such third party rights, as well as obtaining any necessary licenses. For more details: www.lonza.com/legal.